Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: RENE
Market: AIM
Sector: Pharma & Biotech
Market Cap: 32.75M
Website: www.reneuron.com
ReNeuron Group Plc

ReNeuron Group Plc

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron is traded in the NEX Exchange HERE

ReNeuron Group Plc

www.reneuron.com

Interactive graph

col 3
col 4
col 5
col 6

ReNeuron Group Plc RNS Announcements

Date Epic Announcement
16/02/2018 RENE Block Listing Application
13/02/2018 RENE Positive pre-clinical data in nerve injury
26/01/2018 RENE Phase II stroke data presented at AHA conference
23/01/2018 RENE Approval of Share Capital Reorganisation
11/01/2018 RENE Further re Share Capital Reorganisation
05/01/2018 RENE Proposed Share Capital Reorganisation
14/12/2017 RENE Interim results
14/12/2017 RENE Stroke clinical trial regulatory approval in US
08/12/2017 RENE ReNeuron opens US office
13/11/2017 RENE Notification of Interim Results
08/11/2017 RENE Retinal disease clinical trial moves into Phase II
31/10/2017 RENE Positive stroke clinical data & regulatory update
27/10/2017 RENE Wins further UK grant
11/10/2017 RENE PDMR Interest in Shares and Share Options
09/10/2017 RENE Presentation of positive pre-clinical data
12/09/2017 RENE Directors' Interest in Shares and Share Options
06/09/2017 RENE Result of AGM
06/09/2017 RENE AGM Trading Update
01/09/2017 RENE Non-executive Director Appointment
01/09/2017 RENE Block Listing Review and TVR
07/08/2017 RENE Posting of Annual Report and Notice of AGM
04/08/2017 RENE Second Price Monitoring Extn
04/08/2017 RENE Price Monitoring Extension
25/07/2017 RENE Appointment of joint broker
19/07/2017 RENE Board change
29/06/2017 RENE Preliminary Results
19/06/2017 RENE FDA approves cryopreserved hRPC formulation
08/06/2017 RENE Notification of Preliminary Results
05/06/2017 RENE Positive FDA feedback on proposed Phase III study
18/05/2017 RENE Presents positive exosome data at major conference

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use